The paper describes how AvidiMab modifications enhance the interaction (avidity) between the antibody and its target antigen to improve the antibody’s potential therapeutic properties, said Scancell.
This same modification also has demonstrated that Scancell’s tumour-associated glycan (TaG) antibodies can directly kill tumour cells.
Scancell said it has used AvidiMab technology to increase the avidity of TaG antibodies being evaluated for the treatment of cancer.
They are also being developed as antibody-drug conjugates (ADC).
The global therapeutic monoclonal antibody market was estimated to be worth US$150bn in 2019 and is predicted to grow to US$300bn by 2025.
Professor Lindy Durrant, Scancell’s chief scientific officer and author of the paper, said: “We are pleased to have our work published in the prestigious, peer-reviewed journal, Cancer Research.
“Our AvidiMab technology increases the avidity of human antibodies by promoting non-covalent Fc-Fc interactions.
“This modification also causes direct killing of cancer cells by our glycan targeting antibodies, and therefore we believe this technology has the ability to create superior candidates for cancer immunotherapy.”